Quinazoline derivatives and pharmaceutical compositions...

Details Quinazoline derivatives and pharmaceutical compositions... Quinazoline derivatives and pharmaceutical compositions...

2006-03-28

2006-03-28

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S266240, C514S266400, C514S217060, C514S313000, C514S314000, C544S122000, C544S283000, C544S284000, C544S293000

Reexamination Certificate

active

07019012

ABSTRACT:
A compound of general formula Iwherein:Rais a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group;Rbis a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; andRcis a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,or a tautomer, stereoisomer, or salt thereof,particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

REFERENCES:
patent: 5866572 (1999-02-01), Barker et al.
patent: 6127374 (2000-10-01), Bridges
patent: 6153617 (2000-11-01), Bridges
patent: 6251912 (2001-06-01), Wissner et al.
patent: 6344459 (2002-02-01), Bridges et al.
patent: 6627634 (2003-09-01), Himmelsbach et al.
patent: 6673803 (2004-01-01), Thomas et al.
patent: 2001/0044435 (2001-11-01), Himmelsbach et al.
patent: 2002/0032208 (2002-03-01), Lohmann et al.
patent: 2002/0169180 (2002-11-01), Himmelsbach et al.
patent: 2003/0149062 (2003-08-01), Jung et al.
patent: 2003/0191308 (2003-10-01), Hennequin et al.
patent: 2004/0024019 (2004-02-01), Tanimoto et al.
patent: 2005/0085495 (2005-04-01), Soyka et al.
patent: 199 08 567 (1999-02-01), None
patent: 199 11 366 (1999-03-01), None
patent: 566226 (1993-10-01), None
patent: WO 95/20045 (1995-07-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 97/02266 (1997-01-01), None
patent: WO 97/38983 (1997-10-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 99/06378 (1999-02-01), None
patent: WO 99/06396 (1999-02-01), None
patent: 99-09016 (1999-02-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 00/18740 (2000-04-01), None
patent: WO 00/31068 (2000-06-01), None
patent: WO-00/51991 (2000-09-01), None
patent: WO 00/55141 (2000-09-01), None
patent: WO-00/78735 (2000-12-01), None
patent: WO-01/77104 (2001-10-01), None
Tsou, Hwei-Ru, “ 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity”,J. Med. Chem., 2001, 2719-2734, vol. 44.
U.S. Appl. No. 10/016,280, Himmelsbach et al., filed Dec. 2001.

Affiliated with

Also associated with

Rating

Quinazoline derivatives and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives and pharmaceutical compositions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3596859